Dihydrotachysterol
From Wikipedia, the free encyclopedia
|
Dihydrotachysterol
|
|
| Systematic (IUPAC) name | |
| (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-
[(E,2R,5R)-5,6-Dimethylhept-3-en-2-yl]-7a-methyl- 2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]- 4-methylcyclohexan-1-ol |
|
| Identifiers | |
| CAS number | |
| ATC code | A11 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C28H46O |
| Mol. mass | 398.664 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | >99% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Dihydrotachysterol (DHT) is a synthetic vitamin D analog activated in the liver that does not require renal hydroxylation like vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). DHT has a rapid onset of action (2 hours), a shorter half-life, and a greater effect on mineralization of bone salts than does vitamin D.
|
|||||
|
||||||||||||||

